We’re thrilled to share several exciting developments from the third quarter of 2025, including the arrival of a new addition to our commercial product portfolio – Talicia®, a leading triple therapy for the treatment of Helicobacter pylori infections:
- Talicia features include three key advantages – high eradication rates at >90%, simplicity of an
all in one capsule containing the three medicines and low resistance.
- It’s now recognized as a first-line therapy in the American College of Gastroenterology guidelines.
- The product is well established and holds patent protection through 2042.
We’re excited to expand our product line with Talicia, as it has an outstanding product profile and is an excellent strategic match for our company.
During the quarter we remained dedicated to advancing our mission of working together to provide unique products that improve the quality of patient care, and we shared a number of updates on our international expansion efforts:
- In September, we announced the launch of Vibativ® in Saudi Arabia. The launch followed our previously announced agreement with Tabuk Pharmaceutical Manufacturing Company for countries in the Middle East.
- In October, we announced the approval of our ibuprofen injection product in Mexico which follows our partnership with PiSA Farmaceutica, a Mexican pharmaceutical firm with a well-established injectable business.
- Earlier this year, we announced the approval of Vibativ in China in partnership with SciClone Pharmaceuticals Limited. We are currently working alongside SciClone to launch the product in that large market.
We posted third quarter and year to date financial results, with $31 million in revenue for the first nine months of 2025, a 12% increase over the prior year period. We also delivered $5 million in cashflow from operations so far in 2025.
As we move through the final quarter of the year, we remain focused on our mission, appreciated the dedicated efforts of our team, and look forward to sharing additional updates.